▎ 摘　　要

NOVELTY - Pharmaceutically acceptable carrier material comprises a hydrogel material comprising three distinct materials arranged as triblock copolymers selected from the poly(ethylene glycol), poly(glutamic acid), poly(propylene fumarate), poly(N-hydroxyethyl)-DL-aspartamide, propylene glycol, poly(ethylene oxide), poly(propylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(hedral oligosilsesquioxane), poly(methacrylic acid), poly(vinyl-pyrrolidone), polyacrylamide, poly(isopropylacrylamide), polyphosphazene, peptides, polyaldehyde, tyrosine-derived polycarbonates, methacrylate, polymethacrylate, N-isopropylacrylamide, acrylamide, acrylate, polyacrylate, poly(lactic acid), poly(glycolic acid), poly(lactide-co-glycolide), poly(3,4-ethylenedioxythiophene), graphene oxide, poly(graphene oxide), polycaprolactone, sodium dodecyl sulfate, vinyl phosphonic acid, poly-dimethylsiloxane, titanium, bioactive glass, carbon nanotubes, silicone, silica, and thiolene materials. USE - Pharmaceutically acceptable carrier material for peripheral nerve repair. ADVANTAGE - The pharmaceutically acceptable carrier material provides localized immunosuppression. DETAILED DESCRIPTION - Pharmaceutically acceptable carrier material comprises a hydrogel material comprising three distinct materials arranged as triblock copolymers selected from the poly(ethylene glycol), poly(glutamic acid), poly(propylene fumarate), poly(N-hydroxyethyl)-DL-aspartamide, propylene glycol, poly(ethylene oxide), poly(propylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(hedral oligosilsesquioxane), poly(methacrylic acid), poly(vinyl-pyrrolidone), polyacrylamide, poly(isopropylacrylamide), polyphosphazene, peptides, polyaldehyde, tyrosine-derived polycarbonates, methacrylate, polymethacrylate, N-isopropylacrylamide, acrylamide, acrylate, polyacrylate, poly(lactic acid), poly(glycolic acid), poly(lactide-co-glycolide), poly(3,4-ethylenedioxythiophene), graphene oxide, poly(graphene oxide), polycaprolactone, sodium dodecyl sulfate, vinyl phosphonic acid, poly-dimethylsiloxane, titanium, bioactive glass, carbon nanotubes, silicone, silica, thiolene materials, its chemically modified derivatives, and combinations and its mixtures; polymeric nanoparticles arranged in the hydrogel material; and one or more of immunosuppressive agents, tregs, antibodies, mesenchymal stromal cells, and cells arranged in the hydrogel material. An INDEPENDENT CLAIM is included for a pharmaceutically acceptable carrier material, which comprises a first hydrogel material (504), the first hydrogel material comprising a bulk-eroding hydrogel material comprising three distinct materials arranged as triblock copolymers selected from the poly(ethyle glycol), poly(glutamic acid), poly(propylene fumarate), poly(N-hydroxyethyl)-DL-aspartamide, propylene glycol, poly(ethylene oxide), poly(propylene oxide), poly(vinyl alcohol), poly(acrylic acid), poly(hedral oligosilsesquioxane), poly(methacrylic acid), poly(vinyl-pyrrolidone), polyacrylam ide, poly(isopropylacrylamide), polyphosphazene, peptides, polyaldehyde, tyrosine-derived polycarbonates, methacrylate, polymethacrylate, N-isopropylacrylamide, acrylamide, acrylate, polyacrylate, poly(lactic acid), poly(glycolic acid), poly(lactide-co-glycolide), poly(3,4-ethylenedioxythiophene), graphene oxide, poly(graphene oxide), polycaprolactone, sodium dodecyl sulfate, vinyl phosphonic acid, poly-dimethylsiloxane, titanium, bioactive glass, carbon nanotubes, silicone, silica, thiolene materials, its chemically modified derivatives, and combinations and mixtures; and a multiple of discrete, spherical delivery vehicles doped into the first hydrogel material, the delivery vehicles (500) comprises a first layer comprising a second hydrogel material (506), where the second hydrogel material is enzymatically degrading; a second layer encapsulating the first layer and comprising a third, hydrogel material, wherein the third hydrogel material is hydrolytically degrading and different from the second hydrogel material; a multiple of spherical polymeric nanoparticles arranged in the first layer, the polymeric nanoparticles comprising a fourth hydrogel material; and one or more T cells arranged in each of the polymeric nanoparticles. DESCRIPTION OF DRAWING(S) - The drawing shows a therapeutic delivery vehicle. 500Delivery vehicle 504First hydrogel material 506Second hydrogel material